MedPAC Seeks Stakeholder Input On Medicare “Least Costly Alternative” Policy
This article was originally published in The Pink Sheet Daily
Executive Summary
Comments by members of the Medicare Payment Advisory Commission at a recent meeting suggest an opportunity for pharmaceutical industry stakeholders to help frame the discussion of Medicare value-based payment approaches for Part B drugs.
You may also be interested in...
IPAB’s Tough Road Ahead Shown As Republicans Opt Not To Help Find Members
House Speaker Boehner and Senate Majority Leader McConnell “respectfully decline” the president’s request to submit names of individuals to serve on the Medicare Independent Payment Advisory Board.
MedPAC Considering Two Options For Reinstating Medicare Least Costly Alternative Policy For Drugs
Both proposals involve legislation that would authorize Medicare Part B to pay for drugs based on the price of the lowest-cost alternative.
Medicare Part B Drug "Least Costly Alternative" Policy Rescinded By CMS
The Centers for Medicare and Medicaid Services has officially notified its contractors to stop using an option to limit payments for Medicare Part B drugs to the "least costly alternative" in a therapeutic class